{"disease":{"id":"ovarian-cancer","name":"Ovarian Cancer","therapeutic_area":"Oncology","data":{"aiSummary":"The treatment landscape for ovarian cancer is evolving, with a shift towards personalized medicine. Platinum-based chemotherapy remains a cornerstone, but PARP inhibitors have significantly improved outcomes, particularly in BRCA-mutated and HRD-positive tumors. Immunotherapy, such as atezolizumab, is being explored in combination with chemotherapy and bevacizumab. Antibody-drug conjugates, like mirvetuximab soravtansine, show promise in FRα-positive tumors. The pipeline includes numerous targeted therapies and novel combinations, aiming to improve survival and quality of life for patients. Liquid biopsies are increasingly used for monitoring and guiding treatment decisions.","drug_count":8,"description":"Ovarian cancer is a malignancy that originates in the ovaries, fallopian tubes, or peritoneum. The most common type is epithelial ovarian cancer, which arises from the cells on the surface of the ovary. The disease often presents at an advanced stage, contributing to its poor prognosis. Treatment typically involves surgery and chemotherapy, with targeted therapies emerging as important options.","subtype_count":9},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.954Z","updated_at":"2026-03-25T12:16:34.954Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"pf-07104091-monotherapy-dose-expansion-ovarian","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07104091 monotherapy dose expansion (ovarian)","generic_name":"pf-07104091-monotherapy-dose-expansion-ovarian","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[insert molecular target]","drug_class":"small molecule","quality_score":35,"revenue":"798","mechanism":""},{"drug_id":"rucaparib","indication_name":"Maintenance treatment of BRCA-mutated recurrent ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rubraca","generic_name":"RUCAPARIB","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PARP-1, PARP-2, PARP-3","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rucaparib inhibits PARP enzymes, causing DNA damage and cancer cell death, especially in cells with BRCA1/2 deficiencies."},{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."},{"drug_id":"avutometinib","indication_name":"KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avmapki Fakzynja Co-Pack","generic_name":"AVUTOMETINIB","company_name":"Verastem Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Avmapki Fakzynja Co-Pack works by blocking a protein that helps cancer cells grow."},{"drug_id":"adriacin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pf-07059013","indication_name":"Treatment of certain types of ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07059013","generic_name":"pf-07059013","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pafolacianine","indication_name":"Imaging ovarian cancer and malignant lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytalux","generic_name":"PAFOLACIANINE","company_name":"On Target Labs","drug_phase":"marketed","molecular_target":"Folate receptor alpha","drug_class":"Optical Imaging Agent","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"doxorubicin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"hydroxydaunomycin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cytalux","indication_name":"Imaging ovarian cancer and malignant lesions","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cytalux","company_name":"Ann & Robert H Lurie Children's Hospital of Chicago","drug_phase":"marketed","molecular_target":"Folate receptor alpha","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Advanced ovarian cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"bevacizumab-maly","indication_name":"Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ALYMSYS","generic_name":"BEVACIZUMAB-MALY","company_name":"AMNEAL PHARMS LLC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""}],"pipeline":[{"drug_id":"olaparib-oral-product","indication_name":"Platinum-resistant/refractory high-grade serous ovarian cancer","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."},{"drug_id":"olaparib-200-300-mg-bid-daily","indication_name":"High-grade serous ovarian cancer (idetrexed + olaparib)","indication_type":"pipeline","phase":"Phase 1","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib 200-300 mg BID, daily","company_name":"Repare Therapeutics","drug_phase":"discontinued","molecular_target":"PARP1 and PARP2 (poly(ADP-ribose) polymerase enzymes)","drug_class":"PARP inhibitor (DNA damage response inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits PARP enzymes to block DNA single-strand break repair, inducing synthetic lethality in BRCA-mutant and HR-deficient cancers."},{"drug_id":"endocrine-therapy-1","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 1","generic_name":"endocrine-therapy-1","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 1","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 1"},{"drug_id":"pegylated-liposomal-doxorubicin-pld","indication_name":"Ovarian Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pegylated Liposomal Doxorubicin (PLD)","generic_name":"pegylated-liposomal-doxorubicin-pld","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in","quality_score":null,"revenue":null,"mechanism":"RP2D of maplirpacept (PF-07901801) biweekly of maplirpacept (PF-07901801) from Phase 1 escalation in"},{"drug_id":"endocrine-therapy-2","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endocrine Therapy 2","generic_name":"endocrine-therapy-2","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"Endocrine Therapy 2","quality_score":null,"revenue":null,"mechanism":"Endocrine Therapy 2"},{"drug_id":"pf-06873600","indication_name":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","indication_type":"pipeline","phase":"discontinued","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-06873600","generic_name":"pf-06873600","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"","drug_class":"PF-06873600 tablet for oral dosing","quality_score":null,"revenue":null,"mechanism":"PF-06873600 tablet for oral dosing"}],"offLabel":[],"totalMarketed":15,"totalPipeline":6},"trials":{"data":[{"nct_id":"NCT01267851","title":"Clinical Database and Biobank of Patients With Gynecologic Neoplasms","phase":"","overall_status":"UNKNOWN","enrollment_count":1600000,"lead_sponsor_name":"Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT05506800","title":"Guangzhou Women's Health Cohort Study (GWHCS)","phase":"","overall_status":"SUSPENDED","enrollment_count":1000000,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT04334239","title":"Effectiveness of Care in Certified Cancer Centres in Germany","phase":"","overall_status":"COMPLETED","enrollment_count":670000,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT00058032","title":"CA125 and Ultrasound in Detecting Ovarian Cancer in Postmenopausal Women","phase":"NA","overall_status":"COMPLETED","enrollment_count":202638,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT04473833","title":"Transvaginal Ultrasonography as a Screening Method for Ovarian Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":65000,"lead_sponsor_name":"John R van Nagell","has_results":false},{"nct_id":"NCT06129968","title":"Transforming Ovarian Cancer Diagnostic Pathways","phase":"","overall_status":"RECRUITING","enrollment_count":34000,"lead_sponsor_name":"Professor Sudha Sundar","has_results":false},{"nct_id":"NCT04494945","title":"Identifying and Caring for Individuals With Inherited Cancer Syndrome","phase":"NA","overall_status":"RECRUITING","enrollment_count":27500,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT05142033","title":"Avera Cancer Sequencing and Analytics Protocol (ASAP)","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Avera McKennan Hospital & University Health Center","has_results":false},{"nct_id":"NCT05204342","title":"Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France","phase":"","overall_status":"COMPLETED","enrollment_count":22500,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04145388","title":"Family History Study on Cancer Risk","phase":"NA","overall_status":"UNKNOWN","enrollment_count":18623,"lead_sponsor_name":"Kaiser Permanente","has_results":false},{"nct_id":"NCT05912972","title":"Development and Management of Registry in Patients With Gynecologic Cancer in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":13500,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT03275298","title":"Evolution of the Therapeutic Care in Ovarian Cancer From 2011","phase":"","overall_status":"SUSPENDED","enrollment_count":13331,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT06851429","title":"Ovarian Cancer Identification on CT Using Deep Learning","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12578,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT00342446","title":"A Follow-up Study of Women Evaluated and Treated for Infertility","phase":"","overall_status":"COMPLETED","enrollment_count":12193,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00340600","title":"Continuation of Follow-up of DES-Exposed Cohorts","phase":"","overall_status":"COMPLETED","enrollment_count":10805,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04214782","title":"Detection of Ovarian Cancer Using an Artificial Intelligence Enabled Transvaginal Ultrasound Imaging Algorithm","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT07039552","title":"Development and Validation of an Ovarian Cancer Risk Prediction Model for Family Members of Ovarian Cancer Probands","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT03517332","title":"Circulating Tumor DNA Exposure in Peripheral Blood","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Quantgene Inc.","has_results":false},{"nct_id":"NCT04470921","title":"STOP OVarian CAncer; Implementation of the Opportunistic Salpingectomy in the Netherlands","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT06203106","title":"NYSCF Scientific Discovery Biobank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"New York Stem Cell Foundation Research Institute","has_results":false},{"nct_id":"NCT06515678","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9464,"lead_sponsor_name":"Groupe Hospitalier Pitie-Salpetriere","has_results":false},{"nct_id":"NCT00539162","title":"Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women","phase":"NA","overall_status":"RECRUITING","enrollment_count":8000,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03246841","title":"Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7274,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT00340210","title":"Extended Follow-up of Columbia, MO Serum Bank Participants","phase":"","overall_status":"COMPLETED","enrollment_count":6720,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06717295","title":"The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","phase":"","overall_status":"RECRUITING","enrollment_count":6000,"lead_sponsor_name":"Javier Toledo","has_results":false},{"nct_id":"NCT06440018","title":"INSPIRE: a Multi-Cancer Early Detection Study","phase":"","overall_status":"RECRUITING","enrollment_count":5350,"lead_sponsor_name":"Singlera Genomics Inc.","has_results":false},{"nct_id":"NCT03662204","title":"Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":5133,"lead_sponsor_name":"Exact Sciences Corporation","has_results":false},{"nct_id":"NCT06223763","title":"SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Clinica Universidad de Navarra, Universidad de Navarra","has_results":false},{"nct_id":"NCT05801263","title":"ctDNA Methylation for Epithelial Ovarian Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":5000,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT03667417","title":"Genetic Predisposition to Breast and Ovarian Cancer: Prospective Study of BRCAx Gene Mutation","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT06118307","title":"Shanghai Ovarian Cancer and Family Care Project","phase":"","overall_status":"RECRUITING","enrollment_count":3546,"lead_sponsor_name":"Shanghai First Maternity and Infant Hospital","has_results":false},{"nct_id":"NCT06760507","title":"Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics","phase":"NA","overall_status":"RECRUITING","enrollment_count":3209,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05051722","title":"Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":3110,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04294927","title":"TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"University Medical Center Nijmegen","has_results":false},{"nct_id":"NCT05697601","title":"Predictors of Ovarian Cancer and Endometrial Cancer for Artificial-Intelligence-Based Screening Tools","phase":"","overall_status":"UNKNOWN","enrollment_count":2905,"lead_sponsor_name":"Hasanuddin University","has_results":false},{"nct_id":"NCT07009743","title":"O-RADS MRI System on Early Detection of Ovarian Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2549,"lead_sponsor_name":"Shanghai Gynecologic Oncology Group","has_results":false},{"nct_id":"NCT06324734","title":"Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting","phase":"","overall_status":"COMPLETED","enrollment_count":2506,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03702309","title":"Liquid Biopsy Evaluation and Repository Development at Princess Margaret","phase":"","overall_status":"RECRUITING","enrollment_count":2500,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT06914726","title":"Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes","phase":"NA","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":2488,"lead_sponsor_name":"HealthPartners Institute","has_results":false},{"nct_id":"NCT04927013","title":"Connecting Families to Overcome Ovarian Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":2331,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT07070726","title":"UNTOLD Ovarian Cancer Unmet Needs Survey","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06483425","title":"A Biomarker Exploration Study of Precision Treatment in Ovarian Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Tongji Hospital","has_results":false},{"nct_id":"NCT05334069","title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT06284343","title":"The Gynecological Cancer Associated Thrombosis (GynCAT) Study","phase":"","overall_status":"RECRUITING","enrollment_count":1800,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04235556","title":"Integrated Care Pathway in Oncology (PASSION)","phase":"","overall_status":"UNKNOWN","enrollment_count":1800,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00951496","title":"Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1560,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02324062","title":"Cancer Genetics Hereditary Cancer Panel Testing","phase":"","overall_status":"COMPLETED","enrollment_count":1511,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT03538665","title":"The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University of Alabama at Birmingham","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false}],"total":50},"guidelines":[{"drug_id":"doxil","guideline_body":"FDA label","recommendation":"DOXIL liposomal infusion is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null},{"drug_id":"doxil","guideline_body":"FDA label","recommendation":"DOXIL liposomal infusion is indicated for the treatment of AIDS-related Kaposi's sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.","line_of_therapy":"2L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}